Biomagnetics accepts Los Alamos National Labs’ optical biosensor for disease diagnosis Biomagnetics Diagnostics Corp., a developer of groundbreaking diagnostic systems and technology for HIV, hepatitis, tuberculosis, malaria and cholera detection, and additional innovative systems, today announced it provides recognized delivery of the world’s first built-in optical biosensor for disease analysis. This new kind of diagnostic device originated with the researchers and engineers at Los Alamos National Laboratory for weight loss . THE BUSINESS now programs to proceed with the procedure of ministration and commercialization of the groundbreaking technology.
The EPO is focused on high criteria for quality and creativity, Biomoda CEO Maria Zannes stated. The EPO’s decision to grant our patent can be an important addition to your patent portfolio and could open the entranceway to additional resources of funding to keep our force toward FDA authorization and commercialization. The European Patent Workplace cooperates with the U.S. Patent and Trademark Workplace and the Japan Patent Workplace within a cooperative plan established to boost the effectiveness of the global patent program.. Biomoda to get European patent for porphyrin-based substance to detect cancer Cancer diagnostics firm Biomoda, Inc. of its purpose to grant the business’s patent application linked to a way of using Biomoda’s proprietary porphyrin-based substance to detect tumor and pre-cancerous cells in body liquid and tissue samples.S.